Abstract
Recent advances in the understanding of the mechanisms of neovascularization and the identification of potent angiogenic growth factors have led to the development of therapeutic angiogenesis for treatment of severe ischemic heart disease. Current clinical studies on therapeutic myocardial angiogenesis generally involved the delivery of recombinant protein or gene of the angiogenic growth factors using various different approaches. Although the initial clinical results are encouraging, the potential side effects of these potent angiogenic growth factors remain a major concern. Large-scale, randomized and placebo control studies will be required to demonstrate the clinical benefit of this novel therapeutic treatment of ischemic heart disease.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
